Skip to main content

02-10-2019 | Gastrointestinal cancer | Video

ESMO 2019: Potential of targeted therapy for cholangiocarcinoma shown in ClarIDHy trial

Ghassan Abou-Alfa takes us through the ClarIDHy results, which suggest that ivosidenib could be an option for IDH1-mutated, advanced cholangiocarcinoma (3:37).

Funding for independent interviews at ESMO 2019 was provided in part by F.Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits